CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1

Related Keywords

Ingelheim ,Rheinland Pfalz ,Germany ,Berlin ,Stephan Thalen ,Stefan Anker ,Waheed Jamal ,Stefanie Molkenthin ,Eli Lilly ,Jeff Emmick ,Product Development ,European Medicines Agency ,Boehringer Ingelheim ,Committee For Medicinal Products Human Use ,Preserved Phase ,Medicinal Products ,Human Use ,Professor Stefan Anker ,Heart Failure Cardiologist ,Preserved Principal ,Corporate Vice President ,Cardiometabolic Medicine ,Vice President ,Media Contact ,Thmp ,Ijardiance ,Empagliflozin ,Dult Heart Failure Patients ,Ventricular Ejection Fraction ,Ymptomatic Chronic Heart Failure ,Committee For Medicinal Products ,Diabetes Status ,Mpower Clinical Program ,Clinical Cardiovascular ,Heart Failure ,Ardiovascular ,Prenal ,Etabolic Systems ,